Cargando...
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
BACKGROUND: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and t...
Gardado en:
| Publicado en: | Diabetes Metab Syndr Obes |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4541559/ https://ncbi.nlm.nih.gov/pubmed/26316788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S34418 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|